Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cornus fruit, derived from the plant *Cornus officinalis* Sieb. et Zucc., is a traditional herbal medicine (known as Shanzhuyu in Pinyin) widely used in East Asian practices for its health-promoting properties. It contains bioactive iridoid glycosides such as loganin and morroniside, as well as triterpenoids like oleanolic acid. Pharmacological research indicates that cornus fruit exerts anti-diabetic effects by promoting the release of acetylcholine from nerve terminals, which subsequently activates muscarinic M3 receptors on pancreatic beta cells to enhance insulin secretion. Additionally, it has been shown to inhibit glucagon-induced CREB activation and act as an antagonist for the TH2-specific chemokine receptor CCR3, suggesting potential therapeutic utility in managing type 2 diabetes and allergic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cornus fruit.